Plain-English translation of NCT02860286 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mesothelioma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial examined whether , an oral medication taken twice daily, could help people with mesothelioma (a cancer caused by asbestos exposure) whose disease had returned or stopped responding to chemotherapy. The study focused on patients whose cancer cells had a specific genetic change called BAP1 loss, which researchers believed might make the medication more effective. Participants received the medication and were monitored to see if their cancer improved.
Mesothelioma is a serious cancer with limited treatment options, especially once standard chemotherapy stops working. Researchers discovered that this medication might work differently in cancers with the BAP1 genetic change, offering hope for patients who have run out of other options.
Participants received as pills to take by mouth twice each day. They had check-ups and scans about 6 weeks after starting treatment and then every 12 weeks afterward to see if the cancer was responding. The medication continued until the cancer grew, side effects became too difficult to manage, or the participant chose to stop—whichever came first.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States